Zura Bio Reports Full Year 2025 Results, Confirms Cash Runway Through 2028

summarizeSummary

Zura Bio Ltd. announced its full year 2025 financial results, reporting an increased net loss, but confirmed its cash and equivalents are sufficient to fund operations through the end of 2028 following a recent $144 million public offering.

check_boxKey Events

• Full Year 2025 Financial Results

  Reported a net loss of $68.7 million for 2025, an increase from $52.4 million in 2024, with diluted EPS of $(1.06).

• Extended Cash Runway Confirmed

  Post-financing cash and cash equivalents are expected to support planned operations through at least the end of 2028, following a $144 million public offering in February 2026. This financing was previously announced on March 10, 2026.

• Clinical Program Advancement

  Topline data from the Phase 2 TibuSHIELD study in hidradenitis suppurativa (HS) is anticipated in Q4 2026, and from the Phase 2 TibuSURE study in systemic sclerosis (SSc) in 1H 2027.

auto_awesomeAnalysis

Zura Bio Ltd.'s full year 2025 financial results showed a significant increase in net loss to $68.7 million and a reduction in cash and equivalents (pre-offering) compared to the prior year. However, the report confirmed an extended cash runway through the end of 2028, enabled by a $144 million public offering completed in February 2026. This financing, previously disclosed on March 10, 2026, significantly de-risks the company's operations and provides stability to advance its two Phase 2 clinical programs, with key data readouts anticipated in late 2026 and early 2027. While the increased net loss is a negative, the secured funding is paramount for continued development in a clinical-stage biotechnology company.